

Aide-Mémoire

Minister Brown meeting with representatives of American Chamber of Commerce Australia (AmCham)

Date due to MO:	2 March 2026	Date of Meeting:	4 March 2026
Security level:	IN CONFIDENCE	Reference:	H2026078731
To:	Hon Simeon Brown, Minister of Health		
Consulted:	Pharmac: <input type="checkbox"/>		
Proactive release:	This title is proposed by the Ministry of Health for proactive release: <input type="checkbox"/>		

Contact for telephone discussion

Name	Position	Telephone
Allison Bennett	Group Manager, Health System Settings, Strategy and Policy	s 9(2)(a)
Alison Cossar	Manager, System Enablers, Strategy and Policy	

PROACTIVELY RELEASED

Aide-Mémoire

Minister Brown meeting with representatives of American Chamber of Commerce Australia (AmCham)

Date due:	2 March 2026		
To:	Hon Simeon Brown, Minister of Health		
Security level:	IN CONFIDENCE	Reference:	H2026078731

About the Meeting

Purpose of Meeting: The American Chamber of Commerce (AmCham) Australia have requested this meeting to:

- discuss your priorities for the health system
- discuss how industry can best engage to support the sustainability of New Zealand's health system.

Details of Meeting:

Date: 4 March 2026
Time: 4:00pm – 4.30pm
Venue: Select Committee Room TBC

Attendees The AmCham health delegation of senior executives from major Australian, New Zealand and global healthcare companies. Biographies are attached as Appendix 2.

Organisation AmCham Australia provides a network for US and Australian companies and supports with promoting trade, commerce, and investment to and from Australia. AmCham regularly conducts international trade delegations, study tours, and summits, strengthening economic ties and building personal relationships between the US and Australia.

Ministry representatives

- Audrey Sonerson, Director-General of Health

Other information

- Hon David Seymour, Hon Casey Costello and Hon Matt Doocoy are also meeting with AmCham separately on 4 March

The following have been included to support you at the meeting:

- Content on your current health priorities and AmCham
- Appendix 1: Detailed Speech Notes
- Appendix 2: Biographies

Background and context

1. The American Chamber of Commerce (AmCham) Australia is the largest and most active international chamber of commerce in Australia. They represent significant Australian and American companies and start-ups operating in the Indo-Pacific region. Many of AmCham Australia's members also oversee their company's operations in New Zealand.
2. AmCham Australia and AmCham New Zealand recently held their annual conference for 2026 on 2-3 March in Wellington. The conference discussed the topics of Health, Defence & Security, Technology & Artificial Intelligence, and US Politics and Economic Outlook for the year ahead. Hon Nicola Willis was a keynote speaker.
3. AmCham Australia have indicated their health delegation's interest in discussing an update on the priorities of your health portfolio and how their companies can best engage to support the sustainability of New Zealand's health system.
4. AmCham previously met with you and other health portfolio Ministers (Hons Dooney and Costello) at last year's annual conference in June 2025. They plan to meet with these Ministers and Hon Seymour on 4 March 2026.

Areas of Discussion

5. AmCham's health delegation have shared a range of topics they are interested in discussing. To support a focused and constructive discussion, we have grouped these topics into the following key thematic areas:
 - a. Priorities for health and balancing cost pressures
 - b. Productivity in healthcare and measurement – current initiatives
 - c. Progressing innovative healthcare
 - d. Other areas of interest that may be raised by attendees, included for background.

Priorities for health and balancing cost pressures

Priorities and targets

6. The AmCham health delegation would value your insights on strategic priorities for the health system, and any forthcoming policy directions, to inform industry engagement and partnership opportunities.
7. As well as a clear focus on centring patients in all health decision-making, work has been focused on delivering against the five health targets of faster cancer treatment, improved childhood immunisation, shorter ED waits, shorter waits for first specialist assessments and shorter waits for elective treatment. You also announced a primary care target for better access to general practice appointments to take effect from 1 July 2026.

Balancing cost pressures in the health system

8. While financial performance is stabilising, the health system remains under significant structural cost pressure. These pressures are driven by an ageing population, rising

labour costs, and increasing treatment and technology costs, with workforce shortages and wage growth remaining critical risks.

9. The Government's approach has been to stabilise the system financially first, then drive improved delivery within tight fiscal settings. This includes targeting funding to areas that deliver measurable results for patients, strengthening primary and community care to relieve hospital pressure, and lifting productivity and performance.
10. Hospital and specialist services are the greatest cost pressure point. These services are high-cost, high-demand, and account for a disproportionate share of cost pressures. Therefore, they sit at the centre of the financial recovery pathway.
11. Health New Zealand (Health NZ) remains in a fragile recovery phase, with a clear expectation to return to break-even by 2026/27 through stronger financial discipline and productivity.
12. Though cost-pressure funding provides relief to help balance system pressures, it does not eliminate underlying issues. An uncertain economic outlook and limited fiscal headroom means reprioritisation is essential, and that new investment must be tightly targeted, clearly justified, and aligned to core priorities.

Productivity in healthcare and measurement – current initiatives

13. AmCham has previously highlighted healthcare productivity as key to better access and outcomes amid fiscal constraints. Measurement aims to strengthen accountability and guide funding to interventions that benefit patients, whilst promoting innovation and timely access to treatments. Core measurements include health targets and performance metrics, which are expanded on in the speech notes provided in Appendix One.
14. With members of the health delegation involved in pharmaceutical companies, medical technology and health innovation, AmCham has indicated an interest in discussing productivity in healthcare, investment in medicines, and improving access to medical devices and digital health. The various current initiatives for these areas are outlined below.

Initiatives improving efficiency, access and investment in medicines

Verification Pathway ('Rule of two')

15. The Verification Pathway allows medicines already approved by two trusted overseas regulators to be authorised in New Zealand within 30 days, giving patients faster access to new medicines while reducing regulatory burden across the health system.
16. The Verification Pathway was included as part of the recent Medicines Amendment Act, within Hon David Seymour's portfolio.

Pharmac uplift

17. In 2024, the Government approved a \$604 million uplift to Pharmac's medicines budget over four years to fund additional cancer and other high-impact medicines, directly responding to long-standing concerns about access and alignment with international comparators. This uplift benefits patients by enabling more medicines to be funded

sooner – 66 medicines in the past year alone – benefiting nearly 250,000 New Zealanders.

12-Month prescribing

18. Since 1 February 2026, the new 12-month prescribing initiative is allowing clinicians to issue prescriptions for up to a year, where clinically appropriate, instead of the standard three-month limit. This benefits patients by lowering costs, improving convenience, and supporting continuity of care.

Medical devices and technology

19. Some members of the AmCham health delegation are involved in the MedTech sector, and the Medical Technology Association of New Zealand (MTANZ). There will be interest from the delegation on New Zealand's medical technology environment including regulatory alignment with international standards, market access, and industry engagement.
20. Substantial work underway for medical devices includes progress on the Medical Products Bill and a new approach to medical device procurement.

Medical device regulation within the Medical Products Bill

21. The Medical Products Bill, which will replace the Medicines Act 1981, will introduce a modern, risk-based regulatory framework for medical devices in line with international best practice. This will increase efficiency through reliance on trusted overseas approvals and improve visibility of the device supply chain. It will also allow domestic manufacturers to obtain local approvals that facilitate access to overseas markets.
22. Under the Bill, almost 75% of medical devices would be approved automatically or through reliance pathways, with some devices excluded from regulation altogether. Only around one percent of new devices – highest-risk products without trusted overseas approval – would require further review.
23. Industry has emphasised that harmonisation will reduce the time and cost for manufacturers to bring new devices to multiple markets thereby ensuring patient access, supporting greater choice of products, and leading to cost savings that can be passed on to healthcare providers and patients.
24. Minister Costello is responsible for progressing the Bill and the Ministry is working to introduce the Bill to Parliament in late 2026.

New approach to medical device procurement

25. In September 2025, the Government announced a more coordinated approach to medical device procurement, with Pharmac and Health NZ sharing responsibility across 55 device categories based on their respective strengths. This clearer delineation of roles is intended to reduce duplication, improve consistency, and provide greater transparency and certainty for suppliers engaging with the system.
26. Health NZ, with support from the Ministry of Health and in collaboration with Pharmac, has developed the Health Technology Evaluation Pathway (HTEP) to guide decision-making and implementation for medical devices, digital health technologies, and emerging innovations.

27. Ongoing industry engagement is a key feature of the new model. Agencies are establishing a Supplier Reference Group, with strong interest from MTANZ (which is a member of AmCham NZ), to provide structured feedback on supplier experience as the changes are implemented. The Ministry will provide Ministers with an update on progress in March 2026.

Expanding digital health technology and care

28. Work is underway to optimise digital health technologies and artificial intelligence to improve access to care, lift productivity across the health system, and deliver better outcomes for patients.

24/7 digital GP service

29. The 24/7 digital GP service launched in 2025 is a clear example of the Government's embrace of digital health to provide patient-focused solutions which support a more efficient system.
30. The service provides round-the-clock access to digital general practice consultations, improving access to care, while also diverting non-urgent cases away from emergency departments and enabling earlier intervention. Early outcomes from this effort have been promising with more than 21,700 consultations delivered in its first few months, easing pressure on frontline services.

Artificial Intelligence (AI)

31. The Government's approach to AI in health is to embrace innovation where it improves patient care and productivity, while ensuring strong clinical, technical, and ethical governance.
32. The Ministry of Health and Health NZ have been working together to deploy AI safely, protect privacy, and maintain public trust, supported by a national expert advisory group. We are working with international partners such as Singapore and Australia to share best practice examples and regulatory models before considering how they might inform New Zealand's own unique health care context.
33. Key examples of AI in use in New Zealand healthcare include:
- Every emergency department in the country now has access to AI-powered clinical scribe tools for transcribing consultations and generating clinical notes. This allows clinicians to spend more time with patients and see, on average, an additional patient per shift.
 - An AI-enabled diabetic retinal screening pilot began last year in South Auckland allowing trained community workers to capture images for real-time analysis. This reduces wait times, increases screening volumes, and frees up specialists to focus on more complex cases.

Progressing innovative healthcare

34. The AmCham health delegation have expressed an interest in discussing innovative healthcare, including genomics and clinical trials.

Genomics

35. Safe, evidence-based access to innovative therapies and technologies are being supported by the Ministry of Health and Health NZ's joint work in genomics and precision health.
36. Genomics has significant potential to improve health outcomes for New Zealanders, and realising this potential requires a focused national approach to implementation. Health NZ is currently piloting genomic testing for cancer and rare disorders at Canterbury Health Laboratories, with support from the American biotechnology company Illumina, which is active in several regional AmCham branches internationally.
37. The Cancer Control Agency is working across agencies to develop a national strategy for access of Chimeric Antigen Receptor T-cell (CAR-T) treatments in New Zealand. This is expected to be completed by the end of 2026, ahead of funding applications for specific CAR-T products anticipated in 2027. Agencies are aligning regulatory and operational pathways alongside service delivery planning, workforce training and data infrastructure so that innovative therapies such as CAR-T can move safely and efficiently from clinical trials to patient care.

Clinical trials

38. The Government is supportive of expanding clinical trials and improving system readiness and processes, including exploring ways to accelerate ethics approvals. Health NZ has been asked to provide advice on clinical trials by the end of the financial year.

Medsafe consultation on clinical trial guidelines

39. Medsafe published their consultation outcomes in January 2026, with the revised guideline and new guidance taking effect from 1 July 2026. The update is to reflect changes to international best practice and provide more clarity for those conducting clinical trials. Industry engaged in the consultation and provided broadly positive feedback.

Ethics review

40. Between December 2024 and March 2025, delays in Health and Disability Ethics Committee (HDEC) review timeframes prompted concern from the sector. Since then, 26 new committee members were recruited and trained, and five additional ad-hoc HDEC meetings were held.
41. Combined with a focused effort to accelerate ethics approval application processing and decision making, these actions have substantially improved timeliness. Review timeframes reduced from up to 93 days in December 2024 to 28 days by July 2025.
42. The team are working towards more sustainable solutions. This includes amending the Standard Operating Procedures and Terms of Reference for the HDEC to create efficiencies, improve sector experience and explore cost recovery models. The Ministry will be engaging with industry and stakeholders throughout this process.

s 9(2)(g)(i)

PROACTIVELY RELEASED

Alison

Alison Cossar
Manager, System Enablers
Strategy and Policy

s 9(2)(g)(i)

PROACTIVELY RELEASED

s 9(2)(g)(i)

PROACTIVELY RELEASED

s 9(2)(g)(i)

PROACTIVELY RELEASED

s 9(2)(g)(i)

PROACTIVELY RELEASED

s 9(2)(g)(i)

PROACTIVELY RELEASED

Appendix 2: Biographies (see attachment)

PROACTIVELY RELEASED



AmCham

HEALTH DELEGATION

WELLINGTON, NZ

MARCH 4, 2026



Steve Dodd

*Genomic Solutions and
BioSciences Manager
NZ,
Thermo Fisher Scientific*

Steven is the New Zealand Genomic Solutions and BioSciences Manager for Thermo Fisher Scientific. Originally from the small town of Opunake, Taranaki, he attended the University of Otago from 1994-2002 where he completed a BSc (microbiology), MSc (Microbiology) and PhD (molecular biology/genetics) in conjunction with AgResearch.

He has 22 years' experience in the Life Science and Diagnostic industry with Thermo Fisher Scientific and its legacy companies, Life Technologies and Invitrogen. This experience includes direct field sales and high-level negotiation across Cambridge (UK), New Zealand and Australia, as well as people management and coaching.

He returned to New Zealand in April 2014 to take up a commercial role for the Life Sciences Solutions Group (formerly Life Technologies) of Thermo Fisher Scientific which involves management of the New Zealand Life Sciences team. He is a member of the ANZ leadership team and actively contributes to the business development strategy and employee wellbeing.



ThermoFisher
SCIENTIFIC

Thermo Fisher Scientific is a diversified science innovation, biotechnology, and biomanufacturing company with a mission to help (enable our customers) make the world healthier, cleaner, and safer.

Through its products and service, Thermo Fisher plays a leading role in enabling the development and scaling of major scientific advances in health (diagnostics, medicine & vaccine manufacturing, clinical trials, genomics, advanced therapies, etc.), food safety, environment, clean energy, mining, biosecurity, border security, and law enforcement.

Thermo Fisher is a US\$40B+ (revenue) business with a market capitalisation of US\$240B, employing over 130K colleagues around the world (1,700+ across AU & NZ), and invests over US\$1.3B in R&D every year.



Aliza Glanville
*Country Commercial
Director New Zealand,
Bristol Myers Squibb*


Aliza Glanville, a senior executive and board director with extensive leadership experience across global biopharmaceutical and healthcare organisations in New Zealand and Australia. Aliza is currently Country Commercial Director for Bristol Myers Squibb New Zealand and has previously served as a Board Director and Commercial Lead within multinational organisations. She brings deep expertise in commercialisation, market access, governance, and go-to-market strategy, and has successfully led high-performing teams and governed multinational businesses exceeding \$300 million in revenue. Known for her strategic insight, collaborative leadership style, and strong stakeholder engagement, Aliza is passionate about driving sustainable growth and improving outcomes for patients and healthcare systems. She holds a Bachelor of Science in Neuroscience and Pharmacology, postgraduate qualifications in Marketing and Business Administration, and is progressing toward Chartered Director status with a Certificate in Company Direction.



Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines for patients with serious diseases. Guided by a strong focus on science and patient outcomes, the company concentrates on areas of high unmet medical need and applies differentiated research platforms and therapeutic modalities to advance medical innovation and improve health outcomes worldwide.

Bristol Myers Squibb works collaboratively with governments, health systems, clinicians, researchers and patient communities to support timely access to innovative therapies and to contribute to sustainable, evidence-based healthcare systems. The company's approach emphasises the responsible generation and use of clinical and real-world evidence, the translation of scientific advances into meaningful patient benefit, and the long-term value of innovation in addressing complex and serious diseases.

Through its global footprint and partnerships, Bristol Myers Squibb seeks to support public health priorities, strengthen health system resilience and contribute constructively to policy discussions focused on improving patient outcomes, equity of access and the sustainability of healthcare systems. The company is committed to operating with integrity, transparency and accountability in its engagement with governments and public institutions.



Mike Hearn
*Executive Director,
AmCham New Zealand*

Mike Hearn was educated in the UK and has been in New Zealand since 1981. He has a background in international banking and trade finance in the UK, USA, and New Zealand. Mike has been the Executive Director of the American Chamber of Commerce in New Zealand Inc. since 1998. Mike is Chairman and Trustee of New Zealand Robotics Charitable Trust since 2008 – teaching kids robotics using the Vex program. Mike is an Executive Committee member of the Canada New Zealand Business Association Inc since 1988, a former Board member of US-NZ Council, Washington, DC, USA 2000- 2014; and former Board member of NZ-US Council, Auckland, 2004-2014.



AmCham New Zealand has been promoting trade, investment, tourism and education links between the United States of America and New Zealand for almost 60 years. Their membership is diverse and is made up of many of the US Fortune 500 companies and leading NZ corporates, and SME's representing turnover well in excess of \$50 billion and over 100,000 employees.

They work closely with many organisations, governmental and business, in both countries as well as with our counterparts in the Asia-Pacific region and this network provides their members with access privileges other organisations are unable to provide.



Kate King
*Government Affairs
Director,
Medtronic*

Kate joined Medtronic in early 2019 in a senior Government Affairs and Policy role. Prior to commencing with Medtronic, Kate worked in the financial services sector leading a project with large corporates and the not-for-profit sector focussed on building greater resilience to natural disaster events.

Previously, Kate spent over a decade working in diverse public policy roles in Australia, including in senior roles in Ministerial Offices, and also in the United Kingdom's Cabinet Office. She also has experience in the not-for-profit sector in the UK.

Kate is on the MTAA's Public Affairs Committee, and was elected to the Board of the Medical Technology Association of New Zealand in June 2024. Kate is also the Chair of the AMCHAM Health Committee.

Medtronic

Medtronic is a global leader in medical technology, services and solutions with our mission to alleviate pain, restore health, and extend life. At Medtronic we aim to transform the lives of our patients, by utilising the latest ground-breaking technology while leveraging our deep understanding of the human body.

Medtronic provides a wide range of products, therapies, and services with the aim of providing a complete continuum of care to diagnose, prevent, treat, and monitor chronic and acute conditions.

Our therapies and solutions span four portfolios to treat more than 70 conditions in the human body across Cardiovascular, Medical Surgical and Neuroscience. Making healthcare better is our priority, and we believe medical technology can play an even greater role in improving people's lives.



Clinton Lubcke
*Senior Manager -
Government Relations,
Stryker*

Clinton has over 20 years of healthcare industry experience across government affairs, market access, public policy and sales & marketing. He joined Stryker in August 2021, after having previously served as Head of Market Access & Government Affairs ANZ at Baxter Healthcare.

Clinton has worked across both MedTech and Pharma sectors, fostering strong relationships between business and policymakers and is an active contributor to the ongoing advocacy efforts of the Medical Technology Association of Australia (MTAA), Medical Technology Association of NZ (MTANZ) and the American Chamber of Commerce in Australia. Clinton played an important role in ensuring ongoing access to Australian made IV fluids during the Covid pandemic and has gone on to positively influence policy agendas in a diverse array of fields including advanced manufacturing, home based care and surgical robotics.

Clinton holds tertiary qualifications including a BSc (Hons) - University of Western Australia, Grad Dip Biotechnology - Melbourne University and Grad Cert Pharmacoeconomics - Monash University.



Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.



James McAdam
*Director, Government
Affairs, Policy and
Advocacy,
Bristol Myers Squibb*

James commenced at Bristol-Myers Squibb in 2017. Prior to his arrival at BMS, James was Senior Adviser in the office of the Minister for Health and Sport. This senior role provided an opportunity to influence policy development and its implementation within healthcare in Australia.

James has developed a strong background in policy, advocacy and government relations gathered over many years working in government, healthcare and the information technology and communications industries. He worked in various roles in campaign politics and for individual Members of Parliament and ministers, before moving into government relations and senior management roles within industry bodies.

In healthcare, James has held positions as Director of Relationships & Advocacy at the Royal Australasian College of Surgeons and as CEO of the Royal Australian & New Zealand College of Obstetricians and Gynaecologists. He served one term as a Director of Eastern Health, Melbourne's largest area health service.

In his role at BMS James is recognised as a leader in policy development and advocacy, articulating complex policy concepts and driving change in diverse areas such as clinical trial reform, PBS/HTA reform and cancer care navigation.

James holds a Bachelor of Arts and post graduate qualifications in humanities and education from La Trobe University. He is a Graduate of the Australian Institute of Company Directors and a Fellow of the Centre for Corporate Public Affairs.



Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines for patients with serious diseases. Guided by a strong focus on science and patient outcomes, the company concentrates on areas of high unmet medical need and applies differentiated research platforms and therapeutic modalities to advance medical innovation and improve health outcomes worldwide.

Bristol Myers Squibb works collaboratively with governments, health systems, clinicians, researchers and patient communities to support timely access to innovative therapies and to contribute to sustainable, evidence-based healthcare systems. The company's approach emphasises the responsible generation and use of clinical and real-world evidence, the translation of scientific advances into meaningful patient benefit, and the long-term value of innovation in addressing complex and serious diseases.

Through its global footprint and partnerships, Bristol Myers Squibb seeks to support public health priorities, strengthen health system resilience and contribute constructively to policy discussions focused on improving patient outcomes, equity of access and the sustainability of healthcare systems. The company is committed to operating with integrity, transparency and accountability in its engagement with governments and public institutions.



Nicholas McGee
*Head of Government
Relations & Policy,
MSD*

Nick is the Head of Government Affairs and Policy for Merck Sharp & Dohme (MSD) Australia & New Zealand. In this role Nick is responsible for overseeing all policy and government relations activities for the company across all of ANZ. Prior to joining MSD, Nick worked in various roles within the pharmaceutical industry and across other industries. Nick is based in Sydney.



At MSD, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities.



Aditi McManus
*Head of Government
Affairs ANZ,
Varian*

Aditi is the Head of Government Affairs, Australia & New Zealand, at Varian, a Siemens Healthineers company. Varian is a global leader in providing technology for cancer care, specialising in radiation therapy. Varian is headquartered in Palo Alto, US.

Aditi has extensive experience in government relations, policy development, stakeholder management and healthcare.

Aditi has held policy leadership roles at the Australian Human Rights Commission, Disability Royal Commission, NSW Health and NSW Premier's Department.

Before coming to Varian, Aditi was the Principal Policy Officer and acting Director of Community Care and Priority Populations at NSW Health in Australia, where she led policy development, program design, and strategic partnerships across various priority population groups, including primary care, women's health, LGBTIQ+ health, refugee and multicultural health.

Aditi is passionate about influencing policy as a pivotal lever to improve health and social equity. Aditi won the inaugural Scope Global Young Achievers Award at Parliament House, Australia, in recognition of her volunteer work in Sri Lanka and as a future change maker.

Aditi holds a Master of Human Rights, Bachelor of Social Work (Honours) and Bachelor of Arts from the University of Sydney.

Aditi is excited to use her expertise and experience to contribute to the development of a vibrant, sustainable healthcare system that promotes innovation and delivers best practice for Australians of all ages and backgrounds.



Varian, a Siemens Healthineers company, develops and delivers advanced technologies that diagnose, plan and treat cancer. We provide radiation therapy systems, imaging solutions, treatment planning software and digital tools that enable clinicians to deliver precise, personalised cancer care. Our technologies support hospitals and cancer centres across the full care pathway — from detection and treatment planning through to therapy delivery and follow-up. By integrating imaging, software and treatment systems, we help clinicians improve accuracy, efficiency and patient outcomes. Together with our partners, we are building a connected oncology ecosystem designed to make high-quality cancer care more accessible worldwide.



Angela Pantano
*Chapter Lead,
Access and Innovation,
Roche*

Starting with over 15 years of clinical nursing experience across New Zealand and England, Angela brings a deeply patient-centric approach in her commercial healthcare leadership roles. Her career is defined by a passion for "working with people, for people," blending a high-level understanding of healthcare delivery with a proven track record in global commercial strategy.

She specialises in navigating complex healthcare policy and access landscapes and successfully commercialising innovative products.

Her expertise includes:

- **Global Commercialization:** Navigating regulatory and reimbursement pathways to launch products across 15 international markets, including Europe, Asia, and Africa.
- **Strategic Leadership:** Leading high-performing, multidisciplinary teams—from managing 65 nurses in Middlemore Hospital's NICU to directing affiliate teams in challenging funding environments.
- **Commercial Acumen:** Expertise in payer negotiations, strategy development, and startup growth within the MedTech and biotech sectors.

By combining innovative thinking with a collaborative leadership style, she has consistently achieved success in some of the world's most demanding healthcare markets. Angela remains committed to driving excellence in patient outcomes through commercial innovation and authentic partnership.



Roche

Roche Diagnostics is part of the Roche Group and is a leading global supplier of diagnostics solutions covering a broad spectrum of medical conditions including cardiovascular disease, infectious disease, oncology and women's health. Roche is a leader in in-vitro diagnostics (IVDs) and tissue-based cancer diagnostics. In 2021, over 27 billion tests were performed globally using one of our solutions. Roche's Diagnostics division in NZ also employs over 50 people and has a broad range of in-vitro diagnostics, digital healthcare tools, disease management and clinical decisions support products. Roche Diagnostics serve customers spanning the entire healthcare spectrum - from research institutions, hospitals and commercial laboratories to physicians and patients.



Brad Porter
*Chief Executive Officer,
Orion Health*

Brad Porter was appointed Chief Executive Officer of Orion Health in August 2022 and now also serves in a dual capacity as Chief Commercial Officer for HEALWELL AI. His expanded role reflects the central position Orion Health holds as HEALWELL's largest and most global business, as well as the opportunity to shape the group's commercial direction on a global scale.

In this expanded capacity, Brad leads the development of HEALWELL's commercial strategy and is responsible for scaling HEALWELL AI's capabilities across international markets, building on the momentum already created through Orion Health's strong customer base, trusted technology platforms, and global partnerships.

Brad brings deep expertise in commercial strategy, global sales, and market expansion. Prior to joining Orion Health, he was General Manager Commercial (International Sales) at Fisher & Paykel Healthcare, where he supported a global sales force of 1,300 across 53 countries. During his tenure, company revenue grew from NZ\$800 million to nearly NZ\$2 billion.

His career began at KPMG, followed by investment and advisory roles at Collier Capital and Kinetic Partners in London. Upon returning to New Zealand, he joined Fisher & Paykel Healthcare's sales team, rising through the ranks to take on global leadership responsibilities.

Brad is passionate about aligning local innovation with international opportunity and delivering scalable digital health solutions that improve population health outcomes and health system sustainability.



Orion Health, a HEALWELL AI company, is a global healthcare technology company focused on reimagining healthcare for all. We are leading the change in digital health by working with health and care organisations to improve the wellbeing of every individual through AI-driven insights, smarter decision-making, and more intelligent coordination across the entire health journey. Orion Health's Unified Healthcare Platform, comprised of the Virtuoso Digital Front Door and the Amadeus Digital Care Record, is underpinned by extensive health and social data sets, machine learning, and over 30 years of innovation focused purely on improving global wellbeing.



Amie O'Mahony
*General Manager,
Government Relations,
AmCham Australia*

Amie O'Mahony joined AmCham in 2013 after a respected career in law. She is based in Sydney.

As General Manager Government Relations, she is responsible for managing all aspects of government affairs, industry and business engagement for the Chamber including acting as Secretariat for AmCham's numerous policy committees and leading advocacy efforts on trade and investment issues impacting members.

Amie began her career as a lawyer specialising in corporate, litigation and insolvency over 14 years ago. An experienced professional, both in Australia and the UK, she has an extensive background in government relations, strategic thinking, negotiation, business development, project management, and stakeholder relations.

Amie is a member of the National Trade Facilitation Committee.

She has a Bachelor of Law from Queensland University of Technology and a Master of Business Administration from Macquarie Graduate School of Management.



The American Chamber of Commerce in Australia (AmCham) is the country's largest international chamber of commerce and premier international business organisation. Founded in 1961, AmCham is known for providing high-level access to opportunity for leading Australian businesses, including over 600 corporate members. AmCham regularly conducts international trade delegations, study tours, and summits, strengthening economic ties and building personal relationships between the United States and Australia.



Andrew Thirlwell
*Director Global Policy
and Public Affairs ANZ,
Pfizer*

Accomplished executive with over 20 years' experience in the life sciences sector in APAC and the UK recognised for leading high performing teams. Adept at navigating complex regulatory environments, market access, crisis management, building coalitions and gaining trust. Passionate about developing colleagues to their full potential with a growth mindset approach building on their strengths.

Inspired by innovation and making sure it reaches those that need it most.



Pfizer is the world's largest leading research-based healthcare company and has a history of more than 115 years in Australia. Pfizer researches, manufactures and markets many of the world's leading medical and healthcare treatments for both humans and animals.

PROACTIVELY RELEASED



Matthew Tyson

*Senior Manager, Market
Access and Partnerships,
Johnson & Johnson*

Matthew Tyson is the Senior Manager for Market Access and Partnerships at Johnson & Johnson, leading strategic initiatives to accelerate access to healthcare innovation for New Zealanders. With extensive experience navigating complex public and private health ecosystems, Matthew works at the intersection of government, industry, and clinical stakeholders to shape sustainable pathways for new technologies and solutions.

Johnson & Johnson

Johnson & Johnson, is a global pharmaceutical company and a subsidiary of Johnson & Johnson Corporation. A member of the top 10 pharmaceutical companies globally, J&J has 40,000 employees working across five continents and invests approximately \$4.5 billion in research and development annually. The J&J team in NZ consists of 4.5 full time employees, and reports into the Australian-New Zealand head office based in Sydney.

Guided by our CREDO, J&J provides prescription medicines for a range of conditions in the areas of haematology, immunology, oncology, mental health, virology, diabetes, neurology, and pain management.



Chris Wynne
*Chief Scientific Officer,
New Zealand Clinical
Research*

Dr Chris Wynne is a physician with expertise in developing new medicines. He has had a clinical career as an oncologist working in Australia, UK, Singapore and New Zealand and is now the Chief Scientific Officer at New Zealand Clinical Research.

His role at NZCR involves engaging with pharmaceutical and biotech companies to transition potential new drugs from the lab and test them in humans for safety and effectiveness. He is responsible for the assessment of the safety of new trial drugs and the integrity of data from clinical trials.

Chris supports the growth of the commercial clinical trial industry in New Zealand by:

- Providing high level scientific advice to biotech and pharma companies
- Training of specialised clinical research physicians and other clinical trial staff
- Supporting efficient regulatory approval for clinical trials

His clinical interests include development of new non-addictive pain drugs, novel drugs for diabetes and weight loss, and gene modifying drugs.



New Zealand Clinical Research group is New Zealand's leading clinical trials company with over 25 years experience in developing new medicines.

With a focus on novel drug research and a commitment to participant safety, NZCR has established itself as a trusted partner for biotech and pharma companies in the development of new medicines and medical treatments. The ability to perform complex clinical research in healthy participants and patients, within New Zealand's robust regulatory environment, has attracted many big Pharma companies to work with NZCR.

As a physician-led organisation employing 900 people, NZCR has a track record of completing over 800 trials involving over 17,000 participants. These studies range from first-in-human clinical trials to phase 3 patient studies, covering research across the entire lifecycle of drug development.

NZCR has early phase dosing units located in Auckland and Christchurch, plus two recruitment and outpatient sites located in Hamilton and Wellington. Later phase trials are conducted by Optimal Clinical Trials, a company within the NZCR group. The recent acquisition of CMax, an Adelaide based clinical trial company, has extended NZCR's capability to recruit healthy participants and patients across a wide range of disease types within another regulatory jurisdiction.

Current exciting areas of research involving NZCR physicians include non-addictive pain drugs, diabetes, obesity, liver disease and gene modifying therapy for common and rare diseases. A full list of current trials, leadership information and further NZCR background is available at www.nzcr.co.nz